HIV診断薬市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別（抗体検査、ウイルス負荷検査、CD4検査、その他）、モード別、最終用途別、地域別、競合別、2020-2030年

世界のHIV診断薬市場は、2024年に45億3,000万米ドルと評価され、2030年には74億7,000万米ドルに達し、CAGR8.68％で成長すると予測されています。

1980年代初頭にエイズが出現して以来、HIV診断薬の状況は大きく進化してきました。診断技術の進歩、一般市民の意識の向上、検査への幅広いアクセスはすべて、HIV/AIDS流行に対する世界の対応において極めて重要な役割を果たしています。今日、HIV診断薬セクターは、ダイナミックで急速に進歩する産業であり、疾病管理の改善、ひいては根絶への新たな希望をもたらしています。

HIV（ヒト免疫不全ウイルス）は、感染防御に重要なCD4細胞を標的とすることで免疫系を損ないます。適時に治療を行わなければ、HIVはAIDS（後天性免疫不全症候群）に進行し、日和見感染症や特定のがんに対する脆弱性を増大させます。継続的な努力にもかかわらず、世界のHIV/AIDSの流行は依然として差し迫った公衆衛生の問題であり、世界中で数百万人が影響を受けています。UNAIDSによると、2019年時点で約3,800万人がHIVとともに生活しています。感染率とエイズ関連死亡率の減少に進展が見られる一方で、持続的な課題は、ウイルスの影響を緩和する上で、入手しやすく正確な診断薬の重要性を強調しています。

市場促進要因

HIV罹患率の上昇が診断薬需要を促進

市場の課題

アクセシビリティと認知度の障壁

市場動向

技術革新が市場拡大を促進

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のHIV診断薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（消耗品、機器、ソフトウェア、サービス）
  • 検査の種類別（抗体検査（HIV-1スクリーニング検査、HIV-1抗体確認検査、HIV-2およびグループO診断検査）、ウイルス量検査、CD4検査、その他）
  • モード別（セルフテスト、ラボベース）
  • 最終用途別（診断検査室、病院・診療所、家庭）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のHIV診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のHIV診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のHIV診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のHIV診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのHIV診断薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Thermo Fisher Scientific, Inc.
• Alere Inc.
• Abbott Laboratories inc.
• Bristol-Myers Squibb Company
• Janssen Global Services, LLC
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• VIIV Healthcare
• Beckman Coulter, Inc.
• Sysmex Europe SE
• Zyomtronix, Inc.
• Mylan N.V.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare GmbH

第15章 戦略的提言

第16章 調査会社について・免責事項

Global HIV Diagnostics market was valued at USD 4.53 billion in 2024 and is projected to reach USD 7.47 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.68%. Since the emergence of AIDS in the early 1980s, the HIV diagnostics landscape has evolved significantly. Advances in diagnostic technologies, increased public awareness, and broader access to testing have all played pivotal roles in the global response to the HIV/AIDS epidemic. Today, the HIV diagnostics sector represents a dynamic and rapidly advancing industry, offering renewed hope for improved disease management and, ultimately, eradication.

HIV (Human Immunodeficiency Virus) compromises the immune system by targeting CD4 cells, critical to defending against infections. Without timely treatment, HIV can progress to AIDS (Acquired Immunodeficiency Syndrome), increasing vulnerability to opportunistic infections and certain cancers. Despite ongoing efforts, the global HIV/AIDS epidemic remains a pressing public health concern, with millions affected worldwide. According to UNAIDS, approximately 38 million individuals were living with HIV as of 2019. While progress has been made in reducing infection rates and AIDS-related mortality, persistent challenges underscore the importance of accessible, accurate diagnostics in mitigating the virus's impact.

Market Drivers

Rising HIV Prevalence Fueling Demand for Diagnostics

The growing global prevalence of HIV/AIDS continues to be a major driver of the HIV diagnostics market. As per the World Health Organization (WHO), around 39.9 million people were living with HIV at the end of 2023, with Sub-Saharan Africa remaining the most affected region, accounting for over two-thirds of global cases. However, HIV continues to affect populations worldwide, reinforcing the universal demand for reliable diagnostic solutions.

Despite preventive measures and treatment advancements, the incidence of new HIV infections remains concerning. In 2023 alone, an estimated 1.3 million individuals acquired HIV. Contributing factors include limited access to preventive education, lack of contraceptive availability, and ongoing social stigma, which impedes testing and treatment efforts. The growing global population also means a rise in the absolute number of individuals living with HIV, thereby intensifying the need for early detection and clinical management.

Timely diagnosis is essential for initiating antiretroviral therapy (ART), which improves quality of life and reduces the risk of transmission. Early detection also helps prevent disease progression to AIDS, subsequently lowering mortality rates. In 2023, AIDS-related illnesses claimed approximately 630,000 lives worldwide. As such, the increasing burden of HIV has bolstered the demand for robust diagnostic tools, reinforcing their role in treatment planning, prevention, and public health management.

Market Challenges

Barriers to Accessibility and Awareness

Despite advancements, significant challenges persist, particularly in low- and middle-income countries where healthcare systems often lack the resources necessary for effective HIV diagnosis. In many rural and underserved areas, diagnostic services are limited due to poor infrastructure, inadequate transportation, and a shortage of trained medical personnel. These systemic gaps lead to late diagnoses and delayed treatment initiation.

Even in areas where diagnostic tools are available, factors such as inconsistent electricity supply, inadequate refrigeration for test kits, and substandard sanitary conditions compromise test accuracy. Moreover, social stigma, fear of discrimination, and misinformation continue to deter individuals from seeking testing. Misperceptions about personal risk and reluctance to discuss sexual health further hinder diagnosis efforts. In regions where comprehensive sex education is lacking, knowledge gaps contribute to the continued spread of HIV.

Cultural and language barriers, as well as insufficiently localized public health campaigns, further limit the effectiveness of outreach programs. Bridging these gaps requires a multifaceted strategy, including investment in healthcare infrastructure, community-based awareness initiatives, and integration of HIV testing into routine healthcare services. Closing the accessibility and awareness gap is crucial for improving early detection and reducing global HIV transmission rates.

Market Trends

Technological Innovation Driving Market Expansion

The HIV diagnostics market has been notably influenced by continuous advancements in testing technologies. One of the most transformative developments has been the rise of point-of-care testing (POCT) devices. These portable tools deliver rapid results-often within 30 minutes-enabling immediate clinical action and reducing transmission risks. POCT has been particularly valuable in resource-constrained environments lacking advanced laboratory infrastructure.

Nucleic acid testing (NAT) has further enhanced diagnostic accuracy by detecting the virus's genetic material directly, allowing for earlier identification and minimizing false-negative results. In parallel, next-generation sequencing (NGS) technologies have facilitated deeper understanding of HIV strain diversity, which is vital given the virus's high mutation rate. This knowledge supports the development of more targeted diagnostics and therapies.

Modern serological assays, such as chemiluminescence immunoassays and multiplex bead-based platforms, offer improved sensitivity and specificity. These tests can differentiate between HIV-1 and HIV-2 and are less susceptible to false positives.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Alere Inc.
• Abbott Laboratories inc.
• Bristol-Myers Squibb Company
• Janssen Global Services, LLC
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• VIIV Healthcare
• Beckman Coulter, Inc.
• Sysmex Europe SE
• Zyomtronix, Inc.
• Mylan N.V.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare GmbH

Report Scope:

In this report, the Global HIV Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV Diagnostics Market, By Product:

• Consumables
• Instruments
• Software and Services

HIV Diagnostics Market, By Test Type:

• Antibody Tests
• Viral Load Tests
• CD4 Test
• Others

HIV Diagnostics Market, By Mode:

• Self-Test
• Lab-based

HIV Diagnostics Market, By End-use:

• Diagnostic Laboratories
• Hospitals & Clinics
• Home Settings

HIV Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market.

Available Customizations:

Global HIV Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global HIV Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Instruments, Software and Services)
  • 5.2.2. By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others)
  • 5.2.3. By Mode (Self-Test, Lab-based)
  • 5.2.4. By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America HIV Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Test Type
  • 6.2.3. By Mode
  • 6.2.4. By End-use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States HIV Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Mode
      • 6.3.1.2.4. By End-use
  • 6.3.2. Mexico HIV Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Mode
      • 6.3.2.2.4. By End-use
  • 6.3.3. Canada HIV Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Mode
      • 6.3.3.2.4. By End-use

7. Europe HIV Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Test Type
  • 7.2.3. By Mode
  • 7.2.4. By End-use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France HIV Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Mode
      • 7.3.1.2.4. By End-use
  • 7.3.2. Germany HIV Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Mode
      • 7.3.2.2.4. By End-use
  • 7.3.3. United Kingdom HIV Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Mode
      • 7.3.3.2.4. By End-use
  • 7.3.4. Italy HIV Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Mode
      • 7.3.4.2.4. By End-use
  • 7.3.5. Spain HIV Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Mode
      • 7.3.5.2.4. By End-use

8. Asia-Pacific HIV Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Test Type
  • 8.2.3. By Mode
  • 8.2.4. By End-use
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China HIV Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Mode
      • 8.3.1.2.4. By End-use
  • 8.3.2. India HIV Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Mode
      • 8.3.2.2.4. By End-use
  • 8.3.3. South Korea HIV Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Mode
      • 8.3.3.2.4. By End-use
  • 8.3.4. Japan HIV Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Mode
      • 8.3.4.2.4. By End-use
  • 8.3.5. Australia HIV Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Mode
      • 8.3.5.2.4. By End-use

9. South America HIV Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Test Type
  • 9.2.3. By Mode
  • 9.2.4. By End-use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil HIV Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Mode
      • 9.3.1.2.4. By End-use
  • 9.3.2. Argentina HIV Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Mode
      • 9.3.2.2.4. By End-use
  • 9.3.3. Colombia HIV Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Mode
      • 9.3.3.2.4. By End-use

10. Middle East and Africa HIV Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Test Type
  • 10.2.3. By Mode
  • 10.2.4. By End-use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa HIV Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Mode
      • 10.3.1.2.4. By End-use
  • 10.3.2. Saudi Arabia HIV Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Mode
      • 10.3.2.2.4. By End-use
  • 10.3.3. UAE HIV Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Mode
      • 10.3.3.2.4. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Alere Inc.
• 14.3. Abbott Laboratories inc.
• 14.4. Bristol-Myers Squibb Company
• 14.5. Janssen Global Services, LLC
• 14.6. Gilead Sciences, Inc.
• 14.7. Merck & Co. Inc.
• 14.8. VIIV Healthcare
• 14.9. Beckman Coulter, Inc.
• 14.10. Sysmex Europe SE
• 14.11. Zyomtronix, Inc.
• 14.12. Mylan N.V.
• 14.13. F. Hoffmann-La Roche Ltd.
• 14.14. Siemens Healthcare GmbH

15. Strategic Recommendations

16. About Us & Disclaimer